CytomX Therapeutics, Inc. (CTMX)
Stock Price:
$7.45 USD
0.10 (1.36%)
Updated November 27, 11:51 AM EST - Market open
Key Info
| Market Cap |
344.37M |
| Revenue (ttm) |
92.27M |
| Net Income (ttm) |
-53.64M |
| Shares Out |
46.22M |
| EPS (ttm) |
-1.17 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$7.45 |
| Previous Close |
$7.35 |
| Change ($) |
0.10 |
| Change (%) |
1.36% |
| Day's Open |
7.37 |
| Day's Range |
7.30 - 7.47 |
| Day's Volume |
95,813 |
| 52-Week Range |
3.60 - 15.44 |
More Stats
| Market Cap |
344.37M |
| Enterprise Value |
44.90M |
| Earnings Date (est) |
Mar 4, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.22M |
| Float |
44.92M |
| EPS (basic) |
-1.18 |
| EPS (diluted) |
-1.17 |
| FCF / Share |
-0.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.95M |
| Short Ratio |
9.06 |
| Short % of Float |
8.80% |
| Beta |
0.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.73 |
| PB Ratio |
7.10 |
| Revenue |
92.27M |
| Operating Income |
-71.21M |
| Net Income |
-53.64M |
| Free Cash Flow |
-9.36M |
| Net Cash |
299.47M |
| Net Cash / Share |
6.48 |
| Gross Margin |
62.31% |
| Operating Margin |
-77.17% |
| Profit Margin |
-58.10% |
| FCF Margin |
-10.14% |
| ROA |
-11.90% |
| ROE |
-82.41% |
| ROIC |
-61.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (10)
| Buy |
6 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.56*
(68.59% upside)
Low
8.50
Current: $7.45
High
18.00
Target: 12.56
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 57.49 | 59.50 | 71.62 | 15.04 | 7.71 | 5.08 | 0.89 |
| Revenue Growth | -3.38% | -16.92% | 376.12% | 95.06% | 51.9% | 471.73% | - |
| Gross Profit | 57.49 | 59.50 | 71.62 | 15.04 | 7.71 | 5.08 | 0.89 |
| Operating Income | -111 | -77.87 | -46.26 | -59.59 | -33.20 | -29.77 | -14.96 |
| Net Income | -102 | -84.60 | -43.10 | -58.90 | -35.37 | -30.31 | -15.14 |
| Shares Outstanding | 45.34 | 41.66 | 37.17 | 36.23 | 8.60 | 0.99 | 0.77 |
| Earnings Per Share | -2.26 | -2.03 | -1.16 | -1.63 | -4.90 | -35.25 | -24.46 |
| Operating Cash Flow | -140 | -75.52 | 170 | -2.03 | -27.42 | 31.80 | -8.01 |
| Capital Expenditures | -3.50 | -3.79 | -1.56 | -2.12 | -1.59 | -1.66 | -0.73 |
| Free Cash Flow | -144 | -79.31 | 169 | -4.16 | -29.01 | 30.14 | -8.74 |
| Cash & Equivalents | 297 | 437 | 375 | 183 | 188 | 64.50 | - |
| Total Debt | 24.87 | - | - | - | - | 2.99 | - |
| Net Cash / Debt | 272 | 437 | 375 | 183 | 188 | 61.51 | - |
| Assets | 341 | 457 | 398 | 199 | 197 | 73.06 | - |
| Liabilities | 290 | 326 | 328 | 121 | 71.15 | 74.89 | - |
| Book Value | 51.11 | 131 | 69.90 | 78.48 | 126 | -78.54 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CytomX Therapeutics, Inc. |
| Country |
United States |
| Employees |
158 |
| CEO |
Sean A. McCarthy |
Stock Information
| Ticker Symbol |
CTMX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CTMX |
| IPO Date |
October 8, 2015 |
Description
CytomX Therapeutics operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.